Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

Bone

Volumn 22, Issue 4, 1998, Pages 403-408

  Pelger, R C M ^a   Hamdy, N A T ^a   Zwinderman, A H ^b   Nijeholt, A A B Lycklama A ^a   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Bisphosphonates; Bone metastases; Bone pain; Bone resorption; Olpadronate; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OLPADRONIC ACID; OPIATE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PROSTATE CARCINOMA;

EID: 18844463574     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(97)00289-5     Document Type: Article

References (34)

1. Adami S., Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Rec Results Cancer Res. 116:1989;67-72.
2. Adami S., Salvagno G., Guarrere G., et al. Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 134:1985;1152-1154.
3. Carey P. O., Lippert M. C. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 32:1988;403-407.
4. Charhon S. A., Chapuy M. C., Delvin E. E., et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer. 51:1983;918-924.
5. Cresswell S. M., English P. J., Hall R. R., Roberts J. T., Marsh M. M. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol. 76:1995;360-365.
6. Elders J. S., Catalona W. J. Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin N Am. 11:1984;283-295.
7. Elooma I., Kylmälä T., Tammela T. Effect of oral clodronate on bone pain A controlled study in patients with metastatic prostate cancer . Int Urol Nephrol. 24:1992;159-166.
8. Fleisch H. Bisphosphonates Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease . Drugs. 42:1991;919-944.
9. Hortobagyi G. N., Theriault R. L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and bone metastases. N Engl J Med. 335:1996;1785-1791.
10. Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 77:1996;102-106.
11. Jacobs S. C. Spread of prostatic carcinoma to bone. Urology. 11:1983;337-344.
12. Kanis J. A. Clodronate - A new perspective in the treatment of neoplastic bone disease [editorial]. Bone. 8:(Suppl. 1):1987;1-87.
13. Kylmälä T., Tammela T., Risteli L., et al. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites A controlled trial of the Finnish Prostate Cancer Group . Eur J Cancer. 29A:1993;821-825.
14. Maeda H., Koizumi M., Yoshimura K., et al. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 157:1997;539-543.
15. Massud T., Slevin M. K. Pamidronate to reduce bone pain in normocalcaemic patients with disseminated prostate cancer. Lancet. i:1989;1021-1022.
16. Papapoulos S. E. Paget's disease of bone Clinical, pathogenetic and therapeutic aspects . Baillière's Clin Endocrinol Metab. 11:1997;117-143.
17. Papapoulos S. E., Hoekman K., Löwik C. W. G. M., et al. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res. 4:1989;775-781.
18. Papapoulos S. E., Van Holten-Verzantvoort A. T. M. Modulation of tumour-induced bone resorption by bisphosphonates. J Ster Biochem Molec Biol. 43:1992;131-136.
19. Paterson A. H. G., Powles T. J., Kanis J. A., et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;59-65.
20. Pelger R. C. M., Lycklama à Nijeholt A. A. B., Papapoulos S. E. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet. ii:1989;865.
21. Percival R. C., Urwin G. H., Harris S., et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 13:1978;41-49.
22. Percival R. C., Watson M. E., Williams J. L., et al. Carcinoma of the prostate Remission of paraparesis with inhibitors of bone resorption . Postgrad Med J. 61:1985;551-553.
23. Prockop D. J., Udenfriend S. Specific method for analysis of hydroxyproline in tissue and urine. Anal Biochem. 1:1960;228-239.
24. Scher H. I., Yagoda A. Bone metastases Pathogenesis, treatment and rationale for use of resorption inhibitors . Am J Med. 82:(Suppl. 2A):1987;6-27.
25. Schweitzer D. H., Zwinderman A. H., Vermeij P., et al. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 8:1993;175-182.
26. Smith J. A. Palliation of painful bone metastases from prostate cancer using sodium etidronate; results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 141:1989;85-87.
27. Taube T., Kylmälä T., Lamberg-Allardt, et al. The effect of clodronate on bone in metastatic prostate cancer Histomorphometric report of a double-blind randomised placebo-controlled study . Eur J Cancer. 30A:1994;751-758.
28. Tofe A. J., Francis M. D., Harvey W. J. Correlation of neoplasms with incidence and localization of skeletal metastases An analysis of 1,355 disphosphonate bone scans . J Nucl Med. 16:1975;986-989.
29. Torti F. M. Hormonal treatment for prostatic cancer. New Engl J Med. 20:1984;1313-1314.
30. Urwin G. H., Percival R. C., Harris S., et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 57:1985;721-723.
31. Van Holten-Verzantvoort A. T. M., Kroon H. M., Bijvoet O. L. M., et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;491-498.
32. Van Holten-Verzantvoort A. T. M., Zwinderman A. H., Aaronson N. K., et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer. 27:1991;544-549.
33. Vorreuther R., Klotz Th., Engelking R. Clodronate in der palliativen Therapie des ossär metastasierten Prostatakarzinoms. Urologe [A]. 31:1992;63-66.
34. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 71:1993;1098-1109.